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Background: Sarcolipin (SLN), myoregulin (MRLN), and dwarf open reading frame (DWORF) are
transmembrane regulators of the sarcoplasmic reticulum calcium transporting ATPase (SERCA)
that we hypothesized played a role in recurrent exertional rhabdomyolysis (RER).
Objectives: Compare coding sequences of SLN, MRLN, DWORF across species and between
RER and control horses. Compare expression of muscle Ca2+ regulatory genes between RER and
control horses.
Animals: Twenty Thoroughbreds (TB), 5 Standardbreds (STD), 6 Quarter Horses (QH) with RER
and 39 breed-matched controls.
Methods: Sanger sequencing of SERCA regulatory genes with comparison of amino acid
(AA) sequences among control, RER horses, human, mouse, and rabbit reference genomes. In
RER and control gluteal muscle, quantitative real-time polymerase chain reaction of SERCA reg-
ulatory peptides, the calcium release channel (RYR1), and its accessory proteins calsequestrin
(CASQ1), and calstabin (FKBP1A).
Results: The SLN gene was the highest expressed horse SERCA regulatory gene with a uniquely
truncated AA sequence (29 versus 31) versus other species. Coding sequences of SLN, MRLN,
and DWORF were identical in RER and control horses. A sex-by-phenotype effect occurred with
lower CASQ1 expression in RER males versus control males (P < .001) and RER females (P = .05)
and higher FKBP1A (P = .01) expression in RER males versus control males.
Conclusions and Clinical Importance: The SLN gene encodes a uniquely truncated peptide in
the horse versus other species. Variants in the coding sequence of SLN, MLRN, or DWORF were
not associated with RER. Males with RER have differential gene expression that could reflect
adaptations to stabilize RYR1.
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Abbreviations: AA, amino acid; ATP2A1, gene encoding sarcoplasmic reticulum calcium transporting ATPase; BLAT, BLAST-like alignment tool; CASQ1, calsequestrin;
cDNA, complementary DNA; CK, creatine kinase; CT, cycle thresholds; DWORF, dwarf open reading frame; ER, exertional rhabdomyolysis; F, female; FKBP1A, calsta-
bin; G, gelding; GAPDH, glyceraldehyde phosphate dehydrogenase; GYS1, glycogen synthase 1; MRLN, myoregulin; PAS, periodic acid-Schiff's; PCR, polymerase chain
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TB, Thoroughbred; UCSC, University of California, Santa Cruz.
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1 | INTRODUCTION
Exertional rhabdomyolysis (ER) in horses is characterized by multiple
episodes of stiffness, muscle cramping, reluctance to move, and mus-
cle damage and can have many causes.1 Exertional rhabdomyolysis
affects 5%-7% of Thoroughbred (TB) and Standardbred (STD) race-
horses, and recurrence can be so frequent that 17% of ER horses are
unable to race again in the same season.2–4
The term recurrent exertional rhabdomyolysis (RER) has been
used to describe a chronic form of ER in racehorses with a proposed
underlying cause of abnormal myoplasmic calcium (Ca2+) regulation.5,6
This hypothesis was based on finding a lower threshold for inducing a
contracture in isolated skeletal muscle bundles of RER versus control
horses exposed to increasing concentrations of halothane, potassium,
and caffeine, all of which induce Ca2+ release from the sarcoplasmic
reticulum (SR).5,6 In addition, higher caffeine-induced Ca2+ release
was found in cultured myotubes from RER versus control horses, as
detected by Fura-2 fluorescence imaging.7 Further studies of isolated
SR membranes and genetic linkage analysis have not identified an
underlying cause for alterations of Ca2+ regulation in RER.8,9
Recent discoveries regarding fundamental modes of intracellular
Ca2+ regulation have identified additional regulatory mechanisms for
the SR Ca2+ transporting ATPase (SERCA) that may play a role in the
genesis of RER in horses. After contraction, SERCA induces muscle
relaxation by catalyzing the transport of 2 Ca2+ ions into the lumen of
the SR using the free energy from hydrolysis of 1 ATP molecule. Phos-
pholamban (PLN) inhibits SERCA activity and is primarily expressed in
cardiac and slow twitch muscle fibers.10,11 Sarcolipin (SLN), first dis-
covered in 1974 as a peptide that copurifies with SERCA, was subse-
quently found to decrease the Ca2+ affinity of SERCA12 and decrease
the energetic coupling efficiency of SERCA (Ca2+/ATP transport ratio
<2), thereby decreasing SR luminal Ca2+ stores.12–14 In addition, tran-
scripts that previously were annotated as long noncoding RNAs
recently have been found to encode small transmembrane peptides
MRLN and dwarf open reading frame (DWORF) that also regulate the
activity of SERCA in skeletal muscle (Figure 1).15,16 Dwarf open reading
frame has been shown to enhance SERCA activity in the mouse heart
by displacing PLN and, in cell culture models, by displacing SLN and
MRLN (Figure 1). A decrease in SLN and MRLN or increase in DWORF
expression could increase SR Ca2+ stores by decreased SERCA inhibi-
tion (ie, decreased Ca2+ affinity), thereby acting to increase calcium
release channel (RYR1) Ca2+ release and myoplasmic Ca2+ concentra-
tion during contraction and potentially leading to clinical manifestations
of RER.
Our goal was to determine if RER is associated with variants in
the coding sequences of SLN, MRLN, or DWORF, altered expression of
Ca2+ regulatory genes involved in SR Ca2+ uptake and Ca2+ release or
both. The first aim of our study was to compare the coding sequences
of SLN, MRLN, and DWORF in the horse with other species. The sec-
ond aim was to determine if the coding sequences for these genes dif-
fered between RER and control horses. The third aim was to determine
if there was a difference in expression of skeletal muscle Ca2+ regula-
tory genes between horses with and without RER.
2 | METHODS
2.1 | Pilot study
To determine if SERCA1 (expressed in fast twitch type 2 fibers) or
SERCA2 (expressed in cardiac and type 1 muscle fibers) was primarily
expressed in equine gluteal muscle, we initially evaluated transcripts
per million reads from RNA-seq data obtained from gluteal muscle of
6 healthy Arabian horses (NCBI's Gene Expression Omnibus GEO
Series accession number GSE104388). Mean transcripts per million
reads (SD) were 3.7 times higher for SERCA1 (562 ± 152 TPM) than
SERCA2 (243 ± 145 TPM). When muscle fiber type composition was
assessed for 6 of the TBs in our study, we found they had 50% fewer
type 1 fibers than did the Arabian horses used in the RNA-seq ana-
lyses (TB: 8% ± 3% type 1, 92% ± 5% type 2: Arabian 17% ± 3% type
1, 83% ± 8% type 2). Thus, SERCA1 rather than SERCA2 seemed to
be the primary isoform of interest when studying SERCA inhibitors in
TB gluteal muscle.
The study was approved by the Institutional Animal Use and Care
Committee of Michigan State University.
2.2 | Comparative amino acid sequences
The entire coding sequences for SLN and MRLN were identified from
the annotated references genomes of horse (EquCab2; http://ncbi.
nlm.nih.gov/genome/145). Horse coding sequences were verified by
comparison to RNA-seq data for Arabian control horses (NCBI's Gene
Expression Omnibus GEO Series accession number GSE104388) and
comparison to Sanger sequencing described below. Coding sequences
for DWORF were identified in the annotated human and mouse
FIGURE 1 Schematic of key Ca2+ regulatory proteins in skeletal
muscle sarcoplasmic reticulum (SR). Sarcoplasmic reticulum calcium
transporting ATPase (SERCA) is the SR Ca2+ pump with isoform
SERCA1 expressed in fast twitch type 2 fibers and SERCA2 expressed
in slow twitch and cardiac muscle fibers. SERCA is inhibited by
sarcolipin (SLN), phospholamban (PLN), or myoregulin (MRLN).
Phospholamban primarily inhibits SERCA2, and SLN and MRLN inhibit
SERCA1, depending upon species. Dwarf open reading frame
(DWORF) displaces the SERCA inhibitors, PLN, SLN, and MRLN.
FKBP (calstabin) modulates Ca2+ release through the Ca2+ release
channel which has 2 isoforms: RYR2 (cardiac and slow twitch) and
RYR1 (fast twitch muscle fibers). Calsequestrin (CASQ) is the luminal,
high-capacity Ca2+ binding protein, which directly modulates Ca2+
release by RYR. DHPR, the dihydropyridine receptor, is a voltage-
gated Ca2+ channel that triggers RYR to release Ca2+. The legend
(right) indicates the effect of each regulatory protein on myoplasmic
Ca2+ concentration: increase (+) or decrease (−)
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reference genomes and used as a BLAST-like alignment tool (BLAT)
on EquCab2 (University of California, Santa Cruz [UCSC] genome
browser; https://genome.ucsc.edu/). Reads for the equine DWORF cod-
ing sequence were present in the reference genome, but the reads
ended abruptly without a stop codon, suggesting that EquCab2 is not
well assembled in the 30 region of this gene. The RNA-seq data from
Arabian horses (GEO Series accession number GSE104388) was used
to complete the derived equine DWORF sequence.
The amino acid (AA) sequences of PLN, SLN, and MRLN were com-
pared to the human and mouse sequences because these species have
well-established references genomes and to rabbit because we cur-
rently are performing comparative biochemical assays on SR prepara-
tion from horse and rabbit. The 2016 Ensembl (https://useast.ensembl.
org/index.html) was used to evaluate the genome of rabbit (OrynCun;
https://www.ncbi.nlm.nih.gov/assembly/GCF_000003625.3), mouse
(http://www.informatics.jax.org/), and human (GRCh38.p12version). For
rabbit, coding sequences for DWORF from the annotated human and
mouse reference genomes were used to BLAT the respective reference
genomes (UCSC genome browser; https://genome.ucsc.edu/).
We also performed comparative sequence analysis for SLN on
species closely related to the horse including ass (NCBI accession
NW_014638236.1, Genebank ERX607030, ERX607036, ERX607001,)
Przewalski's horse (databases NC_007675973.1, Genebank ATBW010
57363.1), and zebra as well as another Perisodactyl, the Southern white
rhinoceros (http://rohsdb.cmb.usc.edu; LOC101603223). To obtain SLN
sequence for the zebra (unknown genus), we Sanger sequenced muscle
tissue archived in the Neuromuscular Diagnostic Laboratory in the same
blinded fashion as described for RER and control horses.
2.3 | Gene sequencing
2.3.1 | Horses
The SLN sequence was determined for 17 TB (11 females [F], 3 geld-
ings [G], 3 stallions [S]), 5 STD (2 F, 2 G, 1 S), and 6 Quarter Horses
(QH; 3 F, 3 G) that had experienced repeated episodes of ER and had
muscle biopsy specimens archived in the Neuromuscular Diagnostic
Laboratory (Supplemental Table 1). Control horses included 13 TB
(3 F, 10 G), 6 STD (1 F, 5 G), and 3 QH (1 F, 2 G) with no known his-
tory of RER and samples archived in the Neuromuscular Diagnostic
Laboratory. The MRLN and DWORF sequences were determined in a
subset consisting of 3 TB, 3 STD, and 3 QH with RER and 4 TB,
4 STD, and 3 QH controls (Supplemental Table 1). The RER criteria
included a history of repeated episodes of ER reported by the refer-
ring veterinarian and muscle biopsy specimens with normal periodic
acid-Schiff's (PAS) staining for glycogen. Preference for study inclu-
sion was given to horses with numerous episodes of ER, documented
increases in serum creatine kinase (CK) activity and centrally displaced
nuclei on histological examination (Supplemental Table 1). All QH
examined were negative for the glycogen synthase 1 (GYS1) mutation
responsible for type 1 polysaccharide storage myopathy.17 Control
horses had no known history of ER and, for TB and QH, no evidence
of muscle histopathology. Hair samples rather than muscle biopsy
specimens were available from local STD racehorse controls.
2.3.2 | DNA isolation and sequencing
Qiagen DNeasy Blood and Tissue Kit (Qiagen, Germantown, Maryland)
was used to isolate genomic DNA from hair roots, buffy coat, or frozen
muscle samples according to the manufacturer's protocol.
2.3.3 | Primers
Primers were designed using Primer3Plus software18 to cover the pre-
dicted protein coding regions of horse SLN, MRLN, and DWORF as well
as the 50 upstream sequence, likely containing the 50 untranslated
region of the 3 horse genes based on similarities across species. For
SLN, 8 primers were designed to cover the possible noncoding exon
1 (2148 bp) and predicted coding exon 2 (2092 bp; Supplemental
Table 2). The regions sequenced for SLN comprised 6332 bp. For
MLRN, 4 primers were designed to cover noncoding exon 1, possible
noncoding exon 2, noncoding exon 3, and coding exon 4 (Supplemen-
tal Table 2). The region sequenced for MRLN comprised 2747 bp. For
DWORF, based on the open reading frame that begins in exon 1 and
encodes the first 4 AA of the protein with the remaining protein being
encoded in exon 2, 2 primers were designed to cover 500 bp upstream
of the coding sequence, the first 4 AA in exon 1, and exon 2 and the 30
untranslated region.15 The region sequenced for DWORF comprised
1300 bp. Primers are listed in Supplemental Table 2.
2.3.4 | PCR and sequence analysis
Each primer pair was used to amplify intervening genomic DNA using
polymerase chain reaction (PCR) in 25 μL reactions that included 2.0 μL
sample DNA, 12.5 μL Hot Start PCR 2× Master Mix Taq Polymerase
(Thermo Fisher Waltham, MA), 0.5 μL of 20 μM forward and reverse
primers (Invitrogen), and 9.5 μL molecular biology grade water. The PCR
reactions started with 15 minutes at 95C, then 35 cycles of 30 seconds
at 94C, 30 seconds at the primer-specific annealing temperature, and
30 seconds at 72C, followed by a final extension of 10 minutes at 72C.
The PCR products were resolved on 1% agarose gels. The PCR products
then were purified using ExoSAP-IT Product Cleanup (Affymetrix,
Santa Clara, California) and sequenced by the Michigan State Univer-
sity Research Technology Support Facility Genomics Core using the
96-capillary electrophoretic ABI 2730×l platform (Sanger sequencing).
Sequences were aligned to Equcab2.0 (http://ncbi.nlm.nih.gov/
genome/145) and analyzed using Sequencher software (version 5.4.5;
Gene Codes Corporation).
2.4 | Gene expression
2.4.1 | Horses
Muscle samples were obtained prospectively from 14 fit TB RER race-
horses (9 F, 2 G, 3 S; age 5.2 ± 2.4 years) with median serum CK activ-
ity of 251 U/L and mean (SD) CK activity of 970 ± 2166 U/L. Samples
also were obtained from 20 fit control TB racehorses (9 F, 6 G, 5 S; age
3.4 ± 1.6 years) with median CK activity of 250 U/L and mean CK
activity of 267 ± 86 U/L. All horses were housed either at the same
race training center or a nearby racetrack in Lexington, Kentucky
(Supplemental Table 1). The RER horses had a history of episodes of ER
documented by a veterinarian and had not exhibited clinical signs
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within 48 hours of muscle biopsy. Control horses were in training and
had no history of ER. Twelve of the horses used for gene expression
studies also were Sanger sequenced for SLN as described above.
2.4.2 | Primers
Primers for GAPDH, RYR1, SERCA1, CASQ1, DWORF, PLN, MRLN, SLN,
and FKBP1A were designed to cross exon-exon boundaries using
NCBI (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and referen-
cing NCBI EquCab 2.0 (Supplemental Table 3). The glyceraldehyde
phosphate dehydrogenase (GAPDH) gene was used as a housekeep-
ing control because it showed minimal variability and is less variable
across age in skeletal muscle.19
2.4.3 | Muscle biopsies
Gluteus medius muscle biopsy specimens were obtained in the morn-
ing 1-4 hours after jogging or light galloping exercise from a standard-
ized site using a modified Bergstrom biopsy needle as previously
described.20 A portion of the sample was flash-frozen in liquid nitro-
gen and stored at −80C. A second portion was oriented in cross-
section and frozen within 12 hours of sampling in isopentane that
was suspended in liquid nitrogen.
2.4.4 | Muscle histopathology
Cryostat sections (7-μm thick) were stained with hematoxylin and
eosin and PAS and evaluated for the presence of centrally located
nuclei, degenerating myofibers, or macrophages.21
2.4.5 | RNA extraction
Total muscle RNA was isolated from flash frozen samples using TRI-
zol/chloroform extraction after tissue homogenization with a biopul-
verizer (BioSpec Products, Inc, Fartlesville, Oklahoma) as previously
described.22 Treatments with DNase were performed on columns
(Direct-zol RNA MiniPrep Plus, Zymo, Irvine, California) with DNase I
(RNase-free; New England BioLabs, Inc Ipswich, MA) according to
manufacturer's instructions.
2.4.6 | Complementary DNA synthesis
Complementary DNA (cDNA) was made using a high-capacity cDNA
reverse transcription kit (Applied Biosystems, Thermo Fisher Scientific
Waltham, MA). Each 20 μL reaction contained 2 μL of 10× RT Buffer,
0.8 μL of 100 mM dNTPs, 2 μL of RT Random Primers, 1 μL of RT
Enzyme, approximately 1200 ng of sample RNA, and the remaining
volume made up of sterile nuclease-free distilled water. The reactions
then were run in a ProFlex PCR system (Applied Biosystems, Life
Technologies Waltham, MA) under the following conditions: 25C for
10 minutes, 37C for 2 hours, 85C for 5 minutes, and 4C until
recovery. All reactions then were diluted with sterile nuclease-free
distilled water to reach a total volume of 100 μL.
2.4.7 | Quantitative real-time PCR
Genes selected included the Ca2+ release channel (RYR1), calstabin
(FKPB1A), which stabilizes Ca2+ leak from RYR1, and calsequestrin
(CASQ1), a luminal high-capacity Ca2+ binding protein that modulates
RYR1 Ca2+ release. Expression of gene encoding SERCA (ATP2A1), PLN,
SLN, MRLN, and DWORF also was determined. Thermocycling for quanti-
tative real-time polymerase chain reaction (qRT-PCR) was conducted
using EvaGreen dye (Biotium, Inc, Fremont, California), ROX Reference
Dye (Invitrogen, Life Technologies Carlsbad, CA), and Hot Start taq DNA
Polymerase (New England BioLabs, Inc Ipswich, MA), using the QuantStu-
dio 3 Real-Time PCR System (ThermoFisher Scientific Waltham, MA). The
PCR reactions were run in duplicate (20 μL volume reactions). Each reac-
tion contained 2 μL of sample cDNA, 2 μL of 2.5 mM dNTPs, 2 μL of
10× PCR buffer, 1 μL of EvaGreen dye, 1.5 μL of 1:10 ROX reference
dye dilution, 0.125 μL of Hot Start taq DNA Polymerase, 2 μL of 1.6 μM
forward primer, 2 μL of 1600 μM reverse primer, and 7.4 μL of sterile
nuclease-free distilled water. Reactions were run for 40 cycles under the
following conditions: denaturation at 95C for 10 minutes, annealing at
60C for 1 minute; melt curve stages at 95C for 15 seconds, 60C for
1 minute, and 95C for 15 seconds. Cycle thresholds (CT) were automati-
cally calculated by the QuantStudio 3 Real-Time PCR System. For each
gene of interest, 100% geometric efficiency was established. Nontem-
plate controls run for each gene showed no amplification.
2.5 | Statistical analysis
2.5.1 | Quantitative real-time PCR
Relative quantitation of gene expression was calculated by the com-
parative threshold cycle method (2-ΔΔCT) using the CT of GAPDH
TABLE 1 Mean (SD) gene expression relative to GAPDH (ΔCT)
RER females Control females RER males Control males
N = 9 N = 9 N = 5 N = 11
RYR1 5.57 ± 0.64a 5.64 ± 0.82a 5.55 ± 0.65a 5.81 ± 0.66a
FKBP1A 5.19 ± 2.76a 6.36 ± 1.32a 4.31 ± 1.49ab 6.77 ± 0.67a
CASQ1 −2.31 ± 2.14acd −3.32 ± 1.83ad −0.23 ± 1.42b −1.64 ± 1.43bc
ATP2A1 7.98 ± 1.03a 8.06 ± 0.55 a 7.02 ± 1.99a 8.72 ± 1.51a
SLN −4.67 ± 1.74a −5.31 ± 1.68a −3.23 ± 1.24a −4.18 ± 2.34 a
MRLN 6.91 ± 0.69a 7.55 ± 1.20a 7.52 ± 0.91a 6.21 ± 1.16a
PLN 8.27 ± 1.48a 8.12 ± 1.61a 8.42 ± 1.68a 8.53 ± 1.34a
DWORF 7.95 ± 1.41a 7.94 ± 1.07a 7.64 ± 1.14a 8.64 ± 1.61a
Genes include RYR1 and its regulators FKBP1A and CASQ1 as well as SERCA (ATP2A1) and its inhibitors SLN, PLN, and MRLN, plus DWORF which displaces
the SERCA inhibitors. Different letters indicate differences between rows. P ≤ .05.
Abbreviations: ATP2A1, gene encoding sarcoplasmic reticulum calcium transporting ATPase; CASQ1, calsequestrin; CT, cycle thresholds; DWORF, dwarf open
reading frame; FKBP1A, calstabin; GAPDH, glyceraldehyde phosphate dehydrogenase; MRLN, myoregulin; PLN, phospholamban; RER, recurrent exertional
rhabdomyolysis; RYR1, calcium release channel; SERCA, sarcoplasmic reticulum calcium transporting ATPase; SLN, sarcolipin.
936 VALBERG ET AL.
(Table 1). Data was tested for normality using the Shapiro Wilks test.
A 2-way analysis of variance and Tukey post hoc test were per-
formed to examine differences in ΔCT values for RER and control
horses stratified by sex using GraphPad Prism 7 (Graphpad Software,
La Jolla, California).
3 | RESULTS
3.1 | Comparison of AA sequences
3.1.1 | Sarcolipin
The coding sequence of SLN in RER and control horses was truncated
at 29 versus 31 AA relative to the human, mouse, rabbit, and Southern
white rhinoceros sequences. The zebra, ass, and Przewalski’s horse
had the same truncated sequence as did the horse (Supplemental
Table 4). Homology of the horse SLN AA sequence was 77% to rabbit
(24/31), 77% to human (24/31), and 81% to mouse (25/31). Most
importantly, the SLN AA sequence was missing putative regulatory
sites Ser4, Thr5, Cys9, and Tyr31 (Figure 2).32–35
3.1.2 | Myoregulin
The myoregulin (MRLN) AA sequence was similar in length across
species at 46 AA. Sequence identity of horse MLRN was 78% with
rabbit (36/46), 85% with human (39/46), and 74% with mouse
(34/46). Most AA differences occurred in the cytoplasmic domain
with only 1 AA impacting charge, horse neutral Thr15 versus
human and rabbit basic Lys15.
3.1.3 | Dwarf open reading frame
The DWORF peptide was similar in length between horse and
human at 35 AA and was 34 AA in mouse with 3 AA that could not
be deduced from the rabbit reference genome (Figure 2). Sequence
homology of horse DWORF was 86% with human (30/35) and 69%
with mouse (24/35). Amino acid substitutions that altered AA charge
were not identified when comparing AA across horse, human, and
mouse.
3.2 | Coding sequence of SLN, MRLN, DWORF in
RER and control horses
No differences were detected in coding sequences of SLN, MRLN, and
DWORF between RER and control horses.
3.3 | Gene expression
Sarcolipin was the most highly expressed SERCA regulatory gene
(Table 1). No significant difference was found in the expression level
of Ca2+ regulatory genes between control females and control males
or between RER females and control females (Figure 3). An impact of
sex and phenotype was observed in which RER males had signifi-
cantly higher expression of FKBP1A (P = .01) than did control males
(Figure 3). The RER males had lower expression of CASQ1 than did
control females (P < .001) and lower expression than RER females
(P = .05; Figure 3).
FIGURE 2 Amino acid sequence (AA) of SLN, PLN, MRLN, and DWORF derived from mouse, human, and rabbit reference genomes, and Sanger
sequencing of horse genes in the present study. Yellow highlight indicates AA substitution or deletion unique to horse. Green highlight indicates
highly conserved residues near the myoplasmic-membrane interface of SERCA inhibitory peptides.16,23,24 Asterisk (*) indicates regulatory site
residues.10,25–31 Question mark (?) indicates putative phosphorylation sites or lack of consensus sequence for rabbit DWORF from the reference
genome. DWORF, dwarf open reading frame; MRLN, myoregulin; PLN, phospholamban; SERCA, sarcoplasmic reticulum calcium transporting
ATPase; SLN, sarcolipin
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4 | DISCUSSION
In resting striated muscle across all species, Ca2+ is tightly regulated to
maintain 10 000-fold lower myoplasmic Ca2+ than SR luminal Ca2+
concentration because of the activity of SERCA.36 The activity of
SERCA is regulated by myoplasmic Ca2+ and by the inhibitory pep-
tides, PLN and SLN.37 More recently, MRLN in mouse skeletal muscle
and sarcolamban in fly heart have been reported to be important
SERCA inhibitors that have highly conserved protein sequences and
molecular structure across species.16,38,39 Such conservation for over
550 million years suggests an important, conserved system for the
regulation of Ca2+ uptake by SERCA.38 In keeping with this conserva-
tion, the transmembrane domains of SLN, PLN, and MRLN are similar
within genes across species, with only a few conservative AA substitu-
tions in this region in equine MRLN (Leu33 versus Phe33, Ser45 ver-
sus Thr 45) compared to mouse, human, or rabbit. Remarkably,
however, equine SLN is distinct from 67 other species evaluated in
our and other studies in that it is truncated at 29 AA, missing a termi-
nal Tyr residue that has been shown to be directly involved in the inhi-
bition of SERCA.40 Other unique aspects of SLN included missing
potential regulatory residues in the cytoplasmic domain including Ser4
(serine/threonine-protein kinase 16 phosphorylation), Thr5 (calmodu-
lin-dependent protein kinase II phosphorylation), and Cys9 (acyla-
tion).11,32,41 These changes do not prove a functional effect and
potentially would be a fruitful area for future research in horses. In
other species, deletion of Thr5 in SLN has been shown in cardiac
muscle to selectively downregulate SR Ca2+ handling proteins and
decrease SR Ca2+ uptake.34 In addition, the luminal tail of SLN in the
horse was missing the terminal Tyr, which is proposed to functionally
interact with luminal residues in SERCA and to target SLN to the
SR and endoplasmic reticulum.39,42,43 Notably, the 29 AA equine
SLN sequence is also found in zebra and ass, (ERX607036 and
ERX607001) and Przewalski’s horse but not in another Perisodactyl,
the Southern white rhinoceros. Thus, the distinct SLN sequence of
Equus sp. has been present for millions of years, before the diver-
gence of Equus caballus, Equus przewalski, Equus grevi, and Equus
asinus, and suggests a unique mechanism for myoplasmic Ca2+ regu-
lation in the horse.44
A selection advantage for RER is suggested by the fact that STD
horses with RER have faster racing times from a standing start than do
STD without RER and by the high prevalence of RER in STD and TB at
5%-7%.2,3 Small increases in myoplasmic Ca2+ concentration during
muscle relaxation induced by the unique protein sequence of equine
SLN could provide a selection advantage to horses with their superior
athletic capacity by facilitating Ca2+ entry into mitochondria (which
activates ATP production and metabolic processes), activating Ca2+-
dependent signaling pathways important for programming an oxidative
muscle phenotype, and increasing the power of muscle contraction by
initial enhancement of actomyosin force production.45 Whereas slight
increases in myoplasmic Ca2+ could enhance speed and endurance,
excessive increases in myoplasmic Ca2+ lead to persistent myofiber con-
tracture, enhanced reactive oxygen production, activation of proteases,
and myodegeneration.46 Thus, in horses, it is possible that slight alter-
ations in the regulation of myoplasmic Ca2+ result in a fine balance
between enhanced speed on the 1 hand and RER on the other.
The distinctive sequence of equine SLN made it a potential candi-
date gene for RER. However, no differences in SLN coding sequence
were detected among 18 TB, 5 STD, and 6 QH with RER versus con-
trol horses. Coding sequences of MRLN and its inhibitor DWORF also
were evaluated in a small number of horses, but no mutation associ-
ated with RER was identified. Additional resources were not directed
to sequence more horses for MRLN and DWORF, because those RER
horses that were sequenced had repeated episodes of ER of sufficient
concern to submit muscle biopsy samples but no mutations were
found. Multiple causes for RER may exist, some of which may be
breed specific, and individual horses may have mutations in genes that
were not evaluated in our study. However, based on our results, we
propose that there is no high-frequency coding mutation in SERCA
inhibitors SLN or MRLN or the dominant-negative SERCA activator
DWORF in TB, STD, and QH with RER. Sequencing of PLN was not
performed on the horses in our study because PLN had much lower
mRNA expression in skeletal muscle than did SLN and the reference
genomes across species had identical PLN AA sequences. Our results
did not eliminate a PLN mutation as a basis for RER. Previous studies
of RER have failed to identify a single genome-wide significant candi-
date locus for RER, suggesting that multiple genes, strong environ-
mental influences, or both are at play.47,48 The heritability of RER in
TB and STD horses has been estimated at approximately 0.40.49 Envi-
ronmental factors such as sex, diet, fitness, and stress also have been
shown to play important roles in expression of RER.3,49
A previous study of gene expression of RER in gluteal muscle of
4 female and 1 male French STD and 6 male and 4 female control
FIGURE 3 Quantitative real-time polymerase chain reaction for
genes involved in myoplasmic Ca2+ regulation in RER and control
horses stratified by sex and expressed as relative abundance of
transcripts compared to GAPDH and their respective control group
(ΔΔCT). Genes include RYR1 and its regulators FKBP1A and CASQ1 as
well as SERCA (ATP2A1) and its inhibitors SLN, PLN, and MRLN, plus
DWORF which displaces the SERCA inhibitors. Asterisks indicate
difference for FKBP1A at P = .01 and CASQ1 at P = .05. ATP2A1,
gene encoding sarcoplasmic reticulum calcium transporting ATPase;
CASQ1, calsequestrin; DWORF, dwarf open reading frame; FKBP1A,
calstabin; GAPDH, glyceraldehyde phosphate dehydrogenase; MRLN,
myoregulin; PLN, phospholamban; RER, recurrent exertional
rhabdomyolysis; RYR1, calcium release channel; SERCA, sarcoplasmic
reticulum calcium transporting ATPase; SLN, sarcolipin
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STD horses was performed using a mouse-equine microarray.50 In
contrast to the present study, muscle biopsy specimens were taken
within 24 hours of an episode of ER. The previous study found that
gene transcripts involved in muscle fiber Ca2+ homeostasis were mod-
ulated in a way that could increase myoplasmic Ca2+ concentration
with down-regulation of ATP2A1, RYR1, and several other genes
impacting myoplasmic, SR, or mitochondrial Ca2+ load (SLC8A1, UCP2,
ANXA6). The SLN and CASQ1 genes were not included in the array,
and ATP2A1 was found to be upregulated in the same samples using
qRT-PCR. These results are difficult to compare with our study espe-
cially because they were not stratified according to sex and because
the 2 studies sampled RER muscle at different times: between epi-
sodes versus within 1 day of an ER episode.
A sex bias exists for the expression of RER with males being less
prone to RER than females.3,4 It is noteworthy that sex-specific differ-
ences in Ca2+ regulatory gene expression were found in RER horses in
our study. For example, RER males had lower expression of CASQ1
than did RER females (P = .05) and control females (P < .001). A sex
effect of CASQ1 expression and muscle disease is seen in murine
models in which male CASQ1-null mice developed fatal stress-induced
malignant hyperthermic-like reactions, whereas female CASQ1-null
mice were protected.51,52 Calsequestrin is integral in regulating RYR1
Ca2+ release and is the principal Ca2+ binding protein in the SR (50-80
Ca2+ ions bound per molecule CASQ1) during the contraction/relaxa-
tion cycle when Ca2+concentrations are ≥1 mM.53
The gene FKBP1A encodes calstabin which, when bound to RYR1,
stabilizes the channel and in resting muscle decreases Ca2+ leak. The
RER males had significantly higher expression of FKBP1 than control
males. If gene expression translates to protein expression, our results
suggest that an adaptation toward lower myoplasmic Ca2+ concentra-
tion exists in RER males, whereby Ca2+ efflux through RYR1 is
decreased by increased FKBP1A. The finding of altered FKBP1A and
CASQ1 expression in RER horses in our study is novel and clinically
important because of the major roles FKBP1A and CASQ1 play in reg-
ulating RYR1 and excitation-contraction coupling.51,53
Altered expression of genes or proteins involved in myoplasmic
Ca2+ regulation do not necessarily imply that these genes or proteins
have a primary role in causing RER. Abnormal increases in myoplasmic
Ca2+ can be a result both of primary defects in intramuscular Ca2+ reg-
ulation as well as secondary consequences of a loss of myofiber struc-
tural integrity from varied causes.46 For example, diverse diseases
such as dysferlinopathies, α-tocopherol deficiency, myotonic dystro-
phy, and dynamin-dependent centronuclear myopathy all result in
increased expression of SLN in skeletal muscle.54–56 In addition, mice with
dystrophin-deficient muscular dystrophy (mdx model) have increased
CASQ1 expression in quadriceps muscle and abnormally high expression
of SLN protein that correlates with decreased maximum velocity of SR
Ca2+ uptake.57 Thus, altered CASQ1 or FKBP1A expression in RER could
support either an adaptation induced by a primary defect in Ca2+ regula-
tion or a secondary role of myoplasmic Ca2+ in generating RER.
It was not possible in our study to standardize the time interval
between an episode of ER and when the muscle biopsy specimen was
obtained for gene expression analysis. We therefore selected horses
with modest increases in CK activity (median, 251 U/L; maximum,
8453 U/L) to prevent muscle cell damage from being the primary
driver of altered gene expression. A weakness of our study was that
SLN gene expression was evaluated without measurement of SLN pro-
tein expression. Examination of SLN protein content presented chal-
lenges because commercially available antibodies to SLN did not
recognize the unique sequence of equine SLN (personal observation).
Further experiments using a customized anti-horse-SLN antibody would
be necessary to correlate SLN gene and protein expression. The notable
RER sex-specific difference in CASQ1 and FKBP1A expression was an
unexpected finding in our study, and further experiments are needed to
examine their impact on RER in males and females.
In conclusion, our results show that the Equus species has a novel
SLN AA sequence with the potential for unique regulation of the Ca2+
affinity of SERCA. In the horses studied, mutations in the coding
sequences of SLN, MRLN, or DWORF were not identified in TB, STD,
or QH horses with RER. Differential expression of RYR1 regulators
FKPB1A and CASQ1 in RER males suggests that genesis of RER could
be impacted by a sex-specific alteration in myoplasmic Ca2+ regulation.
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